DjiboutiTuberculosis profile
Population  2015 <1 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.35 (0.23–0.49) 39 (26–56)
Mortality (HIV+TB only) 0.035 (<0.01–0.11) 4 (0.26–13)
Incidence  (includes HIV+TB) 3.4 (2.6–4.2) 378 (291–476)
Incidence (HIV+TB only) 0.2 (0.15–0.25) 22 (17–28)
Incidence (MDR/RR-TB)** 0.18 (0.089–0.27) 20 (10–30)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.17 (0.08–0.27) 1.1 (0.58–1.5) 1.2 (0.66–1.8)
Males 0.2 (0.12–0.27) 1.9 (1.4–2.4) 2.1 (1.6–2.7)
Total 0.37 (0.25–0.49) 3 (2.5–3.5) 3.4 (2.6–4.2)
TB case notifications, 2015  
Total cases notified 2 692
Total new and relapse 2 686
          - % tested with rapid diagnostics at time of diagnosis 51%
          - % with known HIV status 90%
          - % pulmonary 57%
          - % bacteriologically confirmed among pulmonary 78%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 80% (64–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.12 (0.07–0.18)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 142 6%
          - on antiretroviral therapy 138 97%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  100
(65–140)
Estimated % of TB cases with MDR/RR-TB 4.3% (1.8–6.8) 34% (21–46)  
% notified tested for rifampicin resistance 5% 930% 1 349
MDR/RR-TB cases tested for resistance to second-line drugs   10
Laboratory-confirmed cases MDR/RR-TB: 85, XDR-TB: 7
Patients started on treatment **** MDR/RR-TB: 71, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 81% 1 240
Previously treated cases, excluding relapse, registered in 2014    
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-02-23 Data: www.who.int/tb/data